Sudo, Kentaro
Nakamura, Yoshiaki http://orcid.org/0000-0002-5241-6855
Ueno, Makoto
Furukawa, Masayuki
Mizuno, Nobumasa http://orcid.org/0000-0001-9704-1885
Kawamoto, Yasuyuki
Okano, Naohiro http://orcid.org/0000-0002-4098-5217
Umemoto, Kumiko
Asagi, Akinori
Ozaka, Masato
Ohtsubo, Koushiro
Shimizu, Satoshi
Matsuhashi, Nobuhisa
Itoh, Shinji
Matsumoto, Toshihiko
Satoh, Taroh
Okuyama, Hiroyuki
Goto, Masahiro
Hasegawa, Hiroko
Yamamoto, Yoshiyuki
Odegaard, Justin I.
Bando, Hideaki
Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Ikeda, Masafumi http://orcid.org/0000-0002-4050-2086
Morizane, Chigusa
Funding for this research was provided by:
SCRUM-Japan Fund
Article History
Received: 27 December 2023
Revised: 10 August 2024
Accepted: 20 August 2024
First Online: 28 August 2024
Competing interests
: KS reports honoraria from Yakult Honsha, Novartis Pharmaceuticals and Ono. Pharmaceutical; and grants for their institution from Bristol-Myers Squibb/Ono Pharmaceutical, Merck, Eisai and Incyte. YN reports advisory role from Guardant Health Pte Ltd, Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Exact Sciences Corporation, Gilead Sciences, Inc.; speakers’ bureau from Guardant Health Pte Ltd., MSD K.K, Eisai Co., Ltd., Zeria Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Becton, Dickinson and Company, Guardant Health Japan Corp; research funding from Seagen, Inc., Genomedia Inc., Guardant Health AMEA, Inc., Guardant Health, Inc., Tempus Labs, Inc./Roche Diagnostics K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd. MU reports honoraria (personal fee) from Taiho Pharmaceutical, AstraZeneca, Yakult Honsha, MSD, Nihon Servier, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, Boehringer Ingelheim, J-pharma, Daiichi Sankyo, Eisai, Takeda Pharmaceutical and Novartis; and research funding (grant) from Taiho Pharmaceutical, AstraZeneca, MSD, Astellas Pharma, Eisai, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, DFP (Delta Fly Pharma), Daiichi Sankyo, Novartis, Boehringer Ingelheim, J-pharma and Chiome Bioscience. N. Mizuno has received grants or contracts from any entity from to his institution from Novartis, MSD, Incyte, Ono Pharmaceutical, Seagen, Dainippon Sumitomo Pharma and Boehringer Ingelheim; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Yakult Honsha, AstraZeneca, Novartis, FUJIFILM Toyama Chemical, Taiho Pharmaceutical and MSD; participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca. YK reports honoraria from Taiho Pharmaceutical, Merck, Yakult Honsha, Ono Pharmaceutical, Incyte, AstraZeneca and Lilly Japan; consulting or advisory role from Taiho Pharmaceutical; and research funding from Japan Agency for Medical Research and Development and Takeda. NO reports honoraria from Taiho Pharmaceutical, Eli Lilly Japan, Eisai, Bayer Yakuhin, Chugai Pharma, Ono Pharmaceutical, Takeda, Daiichi Sankyo, AstraZeneca, MSD and Incyte; advisory board from GlaxoSmithKline; and non-financial support from J-pharma. KU reports honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical and Yakult Honsha. MO reports honoraria from Taiho, Ono, Yakult, Servier, MSD, Pfizer, Bayer and Novartis. SS reports grants from AstraZeneca, Incyte Corporation and Delta-Fly Pharma. TS reports grants and personal fees from Ono pharmaceutical, Chugai-Pharmaceutical, Elli-Lilly, Daiichi-Sankyo and Taiho-Pharmaceutical; and grants from Yakult-Honsha, MSD, Hutch-Med, Shionogi and Jansen, outside the submitted work. MG reports personal fees and non-financial support from Chugai Pharmaceutical, Taiho Pharmaceutical and Ono Pharmaceutical; and personal fees from Eli Lilly Japan K.K. and MSD K.K., outside the submitted work. YY reports honoraria for lectures from Ono Pharmaceutical, Taiho, Bristol Myers Squibb, Servier, Yakult, Takeda, Chugai, Daiichi Sankyo, Lilly, Incyte and Bayer. JIO is an employee and stockholder of Guardant Health. HB reports honoraria from Taiho Pharmaceutical, Eli Lilly Japan and Ono Pharmaceutical; and grants from Ono Pharmaceutical outside the submitted work. TY reports honoraria from Chugai Pharma, Takeda Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical and MSD K.K; consulting fee: Sumitomo Corp.; and research grant/funding: Amgen, Chugai, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia Inc., Molecular Health, MSD, Nippon Boehringer Ingelheim, Ono, Pfizer, Roche Diagnostics, Sanofi, Sysmex and Taiho. MI reports honoraria from Abbott, AbbVie, AstraZeneca, Bayer, Guardant Health Japan, Bristol Myers Squibb, Chugai Pharmaceutical, EA Pharma, Eisai, Fujifilm, Incyte, Lilly Japan, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical, Nihon Servier, Taiho Pharmaceutical, Taisho Pharmaceutical Holdings, Takeda, Teijin Pharma and Yakult Honsha; advisory roles with AbbVie, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Chugai Pharmaceutical, Eisai, Guardant Health Japan, Lilly Japan, MSD, Novartis, Ono Pharmaceutical and Nihon Servier; and research funding from AstraZeneca, Bayer, Bristol Myers Squibb, Chiome Bioscience, Chugai Pharmaceutical, Delta-Fly Pharma, Eisai, InVitae, J-Pharma, Lilly Japan, Merck, Merus NV, MSD, Nihon Servier, Novartis, Ono Pharmaceutical, Pfizer and Syneos Health. CM reports honoraria from Novartis, Yakult Honsha, Teijin Pharma, Taiho Pharmaceutical, Eisai, MSD K.K., and AstraZeneca; consulting fees with Yakult Honsha, MSD K.K., Servier, Boehringer Ingelheim and Taiho; and grants (for the institution) from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck Biopharma, Daiichi Sankyo, HITACHI and Boehringer Ingelheim. MF, AA, KO, N. Matsuhashi, SI, TM, HO and HH have nothing to disclose.
: The study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The protocol of the GOZILA study was approved by the Research Ethics Review Committee of National Cancer Center (National Cancer Center Hospital East; National Cancer Center Hospital) and by the ethics committee/institutional review board of other participating institutions (Aichi Cancer Center; National Hospital Organisation Kyushu Cancer Center; Hokkaido University Hospital; Saitama Cancer Center; Kanagawa Cancer Center; Kansai Rosai Hospital; National Hospital Organisation Shikoku Cancer Center; NHO Osaka National Hospital; University of Tsukuba Hospital; Chiba Cancer Center; Kyorin University Hospital; Kindai University Hospital; Kyushu University Hospital; St. Marianna University School of Medicine; Osaka University Hospital; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Kobe City Medical Center General Hospital; Osaka Medical and Pharmaceutical University Hospital; Gifu University Hospital; Kanazawa University Hospital; Shizuoka Cancer Center; Kagawa University Hospital; Keio University Hospital; Saitama Medical University International Medical Center; Shimane Prefectural Central Hospital; Kansai Medical University Hospital; Kyoto Katsura Hospital; Osaka International Cancer Institute; Osaka General Medical Center). Eligible patients provided written informed consent.
: This manuscript does not contain any individual person’s data such as individual details, images or videos.